DUBLIN — Perrigo Company announced that it has received final approval from the U.S. Food & Drug administration for the store brand over-the-counter (OTC) equivalent of Imodium Multi-Symptom Relief (loperamide hydrochloride and simethicone tablets, 2 mg/125 mg). This product will be packaged and marketed as store brands or retailer ‘own label’ brands and will provide consumers with a high-quality, value alternative to the national brand. Perrigo is finalizing plans to launch its wholly owned store brand loperamide hydrochloride and simethicone tablets, 2 mg/125 mg, in the fourth quarter of 2018.

Imodium Multi-Symptom Relief is indicated to relieve symptoms of diarrhea plus bloating, pressure and cramps, commonly referred to as gas. Retail sales for the last 12 months were approximately $62 million as measured by IRI.

Perrigo executive vice president and president, Consumer Healthcare Americas, Jeff Needham stated, “This final approval and upcoming launch is an important accomplishment for our store brand OTC business. Key new product launches such as loperamide hydrochloride and simethicone tablets, 2 mg/125 mg, provide our customers and consumers with high quality, value alternatives in important treatment categories.”